Drug developer with Duke ties files to go public
BEDMINSTER, N.J. – Aerie Pharmaceuticals Inc., a company spun out of Duke University that’s developing glaucoma treatments, has filed to go public.
The company filed with the U.S. Securities and Exchange Commission to offer shares of the company’s common stock on the NASDAQ.
The clinical-stage pharmaceutical company is developing treatments for glaucoma and other eye diseases.
Its lead product candidate is a once-daily eye drop designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension.
Glaucoma is a progressive disease, in which elevated pressure levels are associated with damage to the optic nerve, resulting irreversible vision loss and potentially in blindness.
Aerie has staff in the Research Triangle Park as well as in Bedminster, N.J., and Newport Beach, Calif.